Journal of Thoracic Oncology - McMaster Experts

publication venue for

Does Patient Experience with Robotic Thoracic Surgery Influence Their Willingness to Pay for It? 2023
Integrating Smoking Cessation Into Low-Dose Computed Tomography Lung Cancer Screening: Results of the Ontario, Canada Pilot 2023
Breathe Anew: Designing and Testing the Feasibility of a Novel Intervention for Lung Cancer Survivorship 2022
Chronic Obstructive Pulmonary Disease Patients Receiving Immunotherapy for Lung Cancer: A Population-Based Study in Canada 2022
EGFR Tyrosine Kinase Inhibitors and Combination Strategies in First-line Treatment of Advanced NSCLC: A Network Meta-analysis 2022
EP04.02-004 The Patient Impact of Liquid Biopsy - Health-Related Quality of Life in Patients Undergoing Liquid Biopsy for Advanced Non-Small Cell Lung Cancer 2022
EP08.02-034 OCELOT - Osimertinib then Chemotherapy in EGFR+ Lung Cancer with Osi Third-line Rechallenge and Osimertinib for Uncommon EGFRm in 1L 2022
International Consensus on Actions to Improve Lung Cancer Survival: Delphi Method in the International Cancer Benchmarking Partnership 2022
OCELOT - Osimertinib then Chemotherapy in EGFR plus Lung Cancer with Osi Third-line Rechallenge and Osimertinib for Uncommon EGFRm in 1L 2022
The Patient Impact of Liquid Biopsy - Health-Related Quality of Life in Patients Undergoing Liquid Biopsy for Advanced Non-Small Cell Lung Cancer 2022
Effects of ALK Tyrosine Kinase Inhibitors in the Treatment of Metastatic NSCLC: A Systematic Review and Meta-Analysis 2021
Move For Surgery - A Novel Preconditioning Program to Optimize Health Before Thoracic Surgery: A Randomized Controlled Trial 2021
OA16.02 The Economic Value of Liquid Biopsy for Genomic Profiling in Advanced Non-Small Cell Lung Cancer 2021
P14.01 Phase 3 Study of First-Line Pembrolizumab ± Vibostolimab (anti-TIGIT) in Patients With PD-L1‒Positive Metastatic NSCLC 2021
P45.10 Effects of ALK Tyrosine Kinase Inhibitors in the Treatment of Metastatic NSCLC: A Systematic Review and Meta-Analysis 2021
Phase 3 Study of First-Line Pembrolizumab +/- Vibostolimab (anti-TIGIT) in Patients With PD-L1-Positive Metastatic NSCLC 2021
Robotic Surgery in Canada: Are Patients Willing to Pay Out-of-Pocket? 2021
Breathe Anew: Designing and Testing the Feasibility of a Novel Intervention for Lung Cancer Survivorship 2021
Chemo-Immunotherapy in First Line Extensive Stage Small Cell Lung Cancer (ES-SCLC): A Systematic Review and Meta-Analysis 2021
Clinical Activity of BMS-986012, an AntieFucosyl-GM1 Monoclonal Antibody, Plus Nivolumab in Small Cell Lung Cancer 2021
Demonstrating VALUE of Liquid Biopsy for Lung Cancer in a Public Healthcare System 2021
FP03.03 Clinical Activity of BMS-986012, an Anti–Fucosyl-GM1 Monoclonal Antibody, Plus Nivolumab in Small Cell Lung Cancer 2021
P89.03 Demonstrating VALUE of Liquid Biopsy for Lung Cancer in a Public Healthcare System 2021
Reporting of Tobacco Use and Impact on Outcomes in Cancer Cooperative Group Clinical Trials: A Systematic Scoping Review 2021
Mapping Mitochondrial Heterogeneity in Lung Cancer 2020
The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma 2020
ES20.03 Tobacco Control Integration in Cancer Care: The Canadian Experience 2019
MA11.04 Platinum Doublet + Durvalumab +/- Tremelimumab in Patients with Advanced NSCLC: A CCTG Phase IB Study - IND.226 2019
MA16.05 Wearable Technology for Preconditioning Before Thoracic Surgery: A Feasibility Study 2019
OA01.02 Endobronchial Ultrasound Staging of Operable NSCLC: Triple Negative Lymph Nodes May Not Require Routine Biopsy 2019
OA09.07 Implementing an Opt-Out Approach to Smoking Cessation Referrals for Cancer Patients in Ontario, Canada 2019
OA12.03 Initial Reporting of NRG-LU001, Randomized Phase II Trial of Concurrent Chemoradiotherapy +/- Metformin HCL in Locally Advanced NSCLC 2019
P1.01-55 Updated Analysis of Outcomes by Histology vs Cytology PD-L1 22C3 Antibody Testing in Advanced Non-Small Cell Lung Cancer 2019
P1.14-33 Canagliflozin Inhibits Lung Cancer Survival and Enhances Its Response to Radiotherapy; Effective Blockade of mTOR Pathway, HIF1a, and Mitosis 2019
MA02.11 Achieving Value in Cancer Diagnostics: Blood Versus Tissue Molecular Profiling - A Prospective Canadian Study (VALUE) 2018
MA13.05 The Canada Lymph Node Sonographic Score: National Validation of a Sonographic Score to Determine Mediastinal Lymph Node Malignancy 2018
MA18.02 The Impact of Treatment Evolution in NSCLC (iTEN) Model: Development and Validation 2018
MA18.03 How in the Real World Are Lung Cancer Patients Treated? The Ontario, Canada Experience 2018
MA18.07 Awareness of the Harms of Continued Smoking Among Lung Cancer (LC) Survivors 2018
MS27.02 Invasive Staging in Medically Inoperable Patients Treated with SBRT: Is It Necessary? 2018
MTE03.01 Inclusion/Exclusion Updates (CNS Mets, Multiple Prior Cancers, Organ Dysfunction) 2018
OA09.01 5As to 3As: Evolution of the Systematic Approach to Smoking Cessation in Ontario’s Regional Cancer Centres 2018
OA09.02 Acceptance of Smoking Cessation Services in Cancer Care Ontario’s Lung Cancer Screening Pilot for People at High Risk 2018
P1.01-02 Long-Term Outcomes with First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up from CheckMate 012 2018
P1.09-04 Optimization of PD-L1 Testing Specimen Flow in the Greater Hamilton, Ontario Region 2018
P1.15-27 Patient Characteristics, Treatment Patterns and Survival for Unresectable Stage III NSCLC in Ontario, Canada 2018
P1.15-28 Real World Treatment Patterns and Survival of Stage IV Non-Small Cell Lung Cancer (NSCLC) in Ontario, Canada 2018
P2.09-08 Clinical Outcomes of Histology Versus Cytology PD-L1 22C3 Antibody Testing in Advanced Non-Small Cell Lung Cancer 2018
P2.10-02 Variations in Smoking Cessation Activities at Ontario’s Regional Cancer Centres 2018
P2.11-23 Risk Perception Among a Lung Cancer Screening Population 2018
P2.13-13 Real-World Study of Osimertinib in EGFR T790M-Mutated Non-Small Cell Lung Cancer (NSCLC): ASTRIS Canadian Cohort Analysis 2018
P2.15-09 The Impact of Treatment Evolution in NSCLC (iTEN) Model: Survival and Cost of Treating Patients with Advanced NSCLC in 2017 2018
P2.15-31 The Evolution of Costs in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Ontario, Canada Between 1999 to 2014 2018
127TiP Phase I study of neo-adjuvant Stereotactic Body Radiotherapy (SBRT) in operable patients with borderline resectable locally advanced NSCLC (LA-NSCLC) (LINNEARRE I STUDY: NCT02433574) 2018
200PD High physician confidence does not predict rate or type of treatment change for cases discussed at a thoracic multidisciplinary cancer conference: A case series in a tertiary cancer center 2018
69P The diabetes drug canagliflozin sensitizes non-small cell lung cancer (NSCLC) to radiotherapy and chemotherapy 2018
A Randomized Phase Ii Trial of Selumetinib plus Platinum-pemetrexed (Pem-c) in Kras Wildtype (Wt)/Unknown NSCLC: CCTG Ind219 2017
MA 10.01 Durvalumab ± Tremelimumab with Platinum-Doublets in Non-Small Cell Lung Cancer: Canadian Cancer Trials Group Study IND.226 2017
MA 18.01 Driving Improvements in Cancer Care Ontario's Smoking Cessation Initiative for Cancer Patients in Ontario, Canada 2017
MA 20.11 Chronic Obstructive Pulmonary Disease Prevalence in a Lung Cancer Screening Population 2017
OA 06.01 Costs and Cost-Effectiveness of Smoking Cessation Within an Organized CT Lung Cancer (LC) Screening Program 2017
OA 15.01 Lung Cancer Screening: Participant Selection by Risk Model – the Pan-Canadian Study 2017
OA 17.03 First-Line Nivolumab plus Platinum-Based Doublet Chemotherapy for Advanced NSCLC: CheckMate 012 3-Year Update 2017
P2.07-029 CheckMate 169: Safety/Efficacy of Nivolumab in Canadian Pretreated Advanced NSCLC (including Elderly and PS 2) Patients 2017
Utilizing PET Imaging to Study Mitochondrial Respiration and Dynamics in Lung Cancer 2017
MA05.06 Diagnosis of Chronic Obstructive Pulmonary Disease in Lung Cancer - A Population Based Study 2017
MA09.03 Cisplatin/Pemetrexed + Durvalumab +/- Tremelimumab in Pts with Advanced Non-Squamous NSCLC: A CCTG Phase IB Study - IND.226 2017
OA03.01 First-Line Nivolumab Monotherapy and Nivolumab plus Ipilimumab in Patients with Advanced NSCLC: Long-Term Outcomes from CheckMate 012 2017
OA17.02 Potential Health and Economic Consequences of Organized vs Opportunistic Lung Cancer Screening in Canada 2017
P1.05-068 Elderly Patients with Resected Stage II Non-small Cell Lung Cancer Are Less Likely to Have a Consultation with a Medical Oncologist 2017
P1.07-050 Patterns of Relapse in Small Cell Lung Cancer (SCLC): A Retrospective Analysis of Outcomes from a Single Canadian Center 2017
P3.07-016 Ontario's Episode-Based Funding Model Reveals Practice Variation in Adjuvant NSCLC Chemotherapy 2017
PUB006 Impact of the New WHO Classification of Thymic Tumors: Cross-Validation of the Prognostic Value in a Single Institution Cohort 2017
CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC 2016
ORAL01.03: CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC 2016
Prognostic Value of the New WHO Thymoma Classification: Single institution Cross Validation Study 2016
Metabolic stress to sensitize non-small cell lung cancer (NSCLC) to radiotherapy: Studies from bench to bedside 2016
NRG-LU001: A phase II trial investigating metformin as a chemo-radio-sensitizer in locally advanced non-small cell lung cancer (NSCLC) 2016
OCOG-ALMERA: A phase II trial investigating the ability of metformin to chemo-radio-sensitize and prevent recurrence in locally advanced (LA) non-small cell lung cancer (NSCLC)∗ 2016
Targeting tumor metabolism to improve radio-sensitivity in non-small cell lung cancer (NSCLC) 2016
A Phase II Study of Dovitinib in Previously-Treated Malignant Pleural Mesothelioma: The Ontario Clinical Oncology Group DOVE-M Trial 2015
Chemoradiotherapy versus Radiotherapy Alone in Elderly Patients with Stage III Non-Small Cell Lung Cancer: A Systematic Review 2015
Clinico-Pathological Correlations and the Role of Brain MRI in Combined Clinical Staging for Resectable Lung Cancer 2015
Comparative Survival in Patients with Brain Metastases from Non-Small Cell Lung Cancer Treated before and after Implementation of Radiosurgery 2015
Cost Efficacy of Tobacco Cessation Versus Treatment of Lung Cancer 2015
Early Results of a Quality Assurance Program in a Randomized Trial of Stereotactic Body Radiotherapy for Stage I Medically Inoperable Lung Cancer 2015
Impact of Time to Drug Approval on Potential Years of Life Lost: The Compelling Need for Improved Trial and Regulatory Efficiency 2015
Impact of Time to Drug Approval on Potential Years of Life Lost: The Compelling Need for Improved Trial and Regulatory Efficiency 2015
Introducing Smoking Cessation Across Ontario's Cancer Treatment System: Early Successes and Continuing Challenges 2015
Robotic Pulmonary Resection for Lung Cancer: Analysis of the Learning Curve in a Novel Surgical Program 2015
Safety and Efficacy of First-Line Nivolumab (NIVO; Anti-Programmed Death-1 [PD-1]) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC) 2015
The Cancer Risk Management Model: A Tool to Inform Canadian Policymakers Implementing Low-Dose CT Screening for Lung Cancer 2015
ADVANCES IN MICRORNAS EXPRESSION PROFILING OF THYMIC EPITHELIAL TUMORS 2014
NIVOLUMAB (ANTI-PD-1; BMS-936558, ONO-4538) IN COMBINATION WITH PLATINUM-BASED DOUBLET CHEMOTHERAPY (PT-DC) OR ERLOTINIB IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) 2014
A RANDOMISED, OPEN-LABEL PHASE II TRIAL OF VOLASERTIB AS MONOTHERAPY AND IN COMBINATION WITH STANDARD DOSE PEMETREXED COMPARED WITH PEMETREXED MONOTHERAPY IN SECOND-LINE NON-SMALL CELL LUNG CANCER (NSCLC) 2013
APPROACH TO BIOMARKER TESTING: PERSPECTIVES FROM VARIOUS SPECIALTIES 2013
ASSESSMENT OF HEALTH CARE PATTERNS FOR ELDERLY LUNG CANCER PATIENTS IN ONTARIO, CANADA 2013
BIENNIAL LUNG CANCER SCREENING BY LOW-DOSE CT SCAN - A SIMULATION OF COST EFFECTIVENESS IN CANADA 2013
BIOMARKER ANALYSIS OF NCIC CLINICAL TRIALS GROUP IND.196, A PHASE I STUDY OF ERLOTINIB PLUS FORETINIB IN ADVANCED PRETREATED NON-SMALL CELL LUNG CANCER PATIENTS 2013
CLINICAL IMPACT OF EGFR MUTATION FRACTION AND TUMOUR CELLULARITY IN EGFR MUTATION POSITIVE NSCLC 2013
EDUCATING COMMUNITY HEALTH PROFESSIONALS ABOUT LUNG CANCER: A PILOT EVALUATION OF A WEB-BASED EDUCATIONAL TOOL 2013
FACTORS ASSOCIATED WITH SMOKING CESSATION IN PARTICIPANTS OF THE PAN CANADIAN EARLY LUNG CANCER STUDY 2013
IMPLEMENTING DYSPNEA MANAGEMENT: A QUALITY IMPROVEMENT PROJECT FOR PATIENTS WITH LUNG CANCER IN ONTARIO, CANADA 2013
MEMORY PRESERVATION WITH CONFORMAL AVOIDANCE OF THE HIPPOCAMPUS DURING WHOLE-BRAIN RADIOTHERAPY FOR PATIENTS WITH BRAIN METASTASES: PRELIMINARY RESULTS OF RTOG 0933 2013
OUTCOMES OF ELDERLY PATIENTS WITH LOCALLY-ADVANCED NON-SMALL CELL LUNG CANCER (LA-NSCLC) TREATED WITH RADIATION plus /- CHEMOTHERAPY AT THE OTTAWA HOSPITAL CANCER CENTRE 2013
RESOURCE CONSTRAINTS AS A BARRIER TO LUNG CANCER MANAGEMENT: DEVELOPED NATIONS 2013
RESOURCE UTILIZATION IN THE LAST THREE MONTHS OF LIFE BY LUNG CANCER PATIENTS IN THE HAMILTON-NIAGARA-HALDIMAND-BRANT LOCAL HEALTH INTEGRATION NETWORK (LHIN) 2013
TECEMOTIDE (L-BLP25) IN UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER IN THE PHASE III START STUDY: FURTHER ENDPOINT AND EXPLORATORY BIOMARKER RESULTS 2013
VARIATION IN THE UPTAKE OF THE COMBINED MODALITY PRACTICE GUIDELINE FOR SURGICALLY UNRESECTABLE STAGE III NSCLC IN ONTARIO 2013
VARIATIONS IN THE UPTAKE OF PRACTICE GUIDELINE RECOMMENDATIONS ON ADJUVANT CHEMOTHERAPY USE FOLLOWING SURGICAL RESECTION IN ONTARIO 2013
VATS REDUCES SURGICAL RISK OF LOBECTOMY FOR HIGH RISK PATIENTS WITH EARLY NON-SMALL CELL LUNG CANCER 2013
MICRORNAS IN THYMIC EPITHELIAL TUMORS: PRELIMINARY DATA 2013
NCIC CTG IND.196: PHASE I STUDY OF FORETINIB (GSK1363089) AND ERLOTINIB IN PATIENTS WITH ADVANCED PRETREATED NSCLC 2012
A Phase II Study of Accelerated Hypofractionated 3-Dimensional Conformal Radiotherapy for Inoperable T1-3 N0 M0 Non-Small Cell Lung Cancer: NCIC CTG BR.25 2012
Cancer Care Ontario's Lung Cancer Disease Pathway Management Initiative: A Novel Approach to Provincial Quality Improvement 2012
Referral of Suspected Lung Cancer by Family Physicians and Other Primary Care Providers: A Clinical Practice Guideline 2012
A PHASE II STUDY EVALUATING CONCURRENT PEMETREXED/CISPLATIN/RADIATION (RT) FOR UNRESECTABLE STAGE IIIA/B NON-SMALL CELL LUNG CANCER (NSCLC) 2011
AN ONTARIO CLINICAL ONCOLOGY GROUP (OCOG) RANDOMIZED TRIAL (PET START) OF FDG PET/CT IN PATIENTS WITH STAGE 3 NON-SMALL CELL LUNG CANCER (NSCLC): IMPACT OF PET ON RADIATION TREATMENT VOLUMES 2011
BIOMARKER DEVELOPMENT FOR A PHASE II STUDY OF COMBINATION EPIGENETIC THERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) 2011
COST-EFFECTIVENESS ANALYSIS COMPARING CONVENTIONAL VERSUS STEREOTACTIC BODY RADIOTHERAPY FOR SURGICALLY INELIGIBLE STAGE I NON-SMALL CELL LUNG CANCER 2011
CRITICAL PERSPECTIVE ON THE TREATMENT OF STAGE IV NON-SMALL CELL LUNG CANCER: COST ANALYSIS OF NEW DRUGS 2011
DO BETA-BLOCKERS ALTER DYSPNEA AND FATIGUE IN ADVANCED LUNG CANCER? A RETROSPECTIVE ANALYSIS 2011
IMPLEMENTATION OF A NATIONAL EGFR TESTING STRATEGY IN A PUBLICLY FUNDED HEALTH SYSTEM 2011
LIMITED RESECTION OF EARLY STAGED LUNG CANCER: A RETROSPECTIVE REVIEW OF OUR DATABASE COMPARING LOBAR RESECTION AND SEGMENTAL AND WEDGE RESECTION. PILOT. 2011
LUNG CANCER DISEASE PATHWAY MANAGEMENT IN ONTARIO, CANADA 2011
LUNG CANCER SCREENING BY LOW DOSE CT (DISCUSSANT) 2011
PROGNOSTIC FACTORS IN THE RADICAL NON-SURGICAL TREATMENT OF STAGE IIIB NON-SMALL CELL LUNG CANCER 2011
PULMONARY FUNCTION AS A PREDICTOR OF LUNG CANCER RISK 2011
THE ANTI-DIABETIC DRUG METFORMIN SENSITIZES HUMAN NON-SMALL CELL LUNG CANCER (NSCLC) XENOGRAFTS TO IONIZING RADIATION. 2011
A Phase I Study of Pomalidamide (CC-4047) in Combination With Cisplatin and Etoposide in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) 2010
A phase II trial of 5-azacitidine (5AC) and entinostat (SNDX-275) in relapsed advanced lung cancer (NSCLC): an interim analysis 2009
Evaluation of the deliverability and tolerability of intensive weekly doublet adjuvant chemotherapy in Non Small Cell Lung Cancer 2009
Management change as a result of positron emission tomography (PET) in a prospective randomized clinical trial 2009
Molecular Targeted Therapy - Can We Afford it? 2009
Overall survival [OS] results of NCIC Clinical Trials Group [CTG] BR.24: a randomized, double-blind trial of carboplatin plus paclitaxel [C plus P] with either daily oral cediranib, a potent inhibitor of all vascular endothelial growth factor receptor tyrosine kinases, or placebo, in advanced non-small cell lung cancer [NSCLC] 2009
Positron emission tomography in small cell lung cancer: a systematic review and practice guideline in Ontario, Canada 2009
Priority health needs for patients receiving concurrent chemotherapy and radiation for stage III non-small cell lung cancer and impact of the role of the advanced practice nurse (APN) 2009
Quality of life (QOL) outcomes with cediranib/placebo in combination with carboplatin/paclitaxel (CP) in advanced non-small cell lung cancer (ANSCLC): results from NCIC CTG BR.24 2009
Strength in numbers - bringing lung cancer patients together through an information fair 2009
Survival of patients with non small cell lung cancer (NSCLC) following diagnosis of brain metastases 2009
The pan-Canadian early detection of lung cancer study 2009
YES WE CAN implement a minimal contact intervention for smoking cessation in 3 minutes or less! 2009
B1-01: A multi-centre phase IIB randomized controlled study of BLP25 liposome vaccine (L-BLP25 or Stimuvax) for active specific immunotherapy of non-small cell lung cancer (NSCLC): updated survival analysis 2007
D5-07: Survival and zoledronic acid-induced normalization of bone marker levels in patients with non-small cell lung cancer 2007
PD3-2-5: Preoperative gefitinib in clinical stage I NSCLC 2007
PD3-2-7: Implications of tumour cavitation on response assessment in trials of Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitors in combination with platinum-based chemotherapy for advanced non-small cell lung cancer (NSCLC): An analysis of trials conducted by the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG). 2007
PD6-1-7: A phase II study of UCN-01 in combination with topotecan in patients (pts) with chemosensitive relapsed small cell lung cancer (SCLC): a study of the Princess Margaret Hospital phase II consortium (PMH-C). 2007
PD6-3-7: Bone metastases from non-small cell lung cancer (NSCLC) result in meaningful skeletal morbidity within a patient’s lifetime 2007
Erratum to "Brief Report: Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171). [Journal of Thoracic Oncology Vol. 18 No. 6: 813-819]".. 19:1578-1579. 2024
EP.08B.03 Prognostic Value of Irradiated Cardiac and Metabolic Tumor Volume in Unresected LA-NSCLC Treated with Concurrent Chemo-Radiotherapy.. 19:s566. 2024
MA01.07 Long-Term Analysis of NRG-LU001, Randomized Phase II Trial of Concurrent Chemoradiotherapy (ccrt) -/+ Metformin in Locally Advanced NSCLC.. 19:s53-s54. 2024
MA14.07 Access Disparities to Lung Cancer Radiotherapy Across Brazil: An Observational Analysis. 19:s112. 2024
P2.10B.03 Efficacy of Platinum Pemetrexed in Patients with EGFR Mutated Advanced Lung Cancer after Progression on Osimertinib - A Prospective Cohort Study. 19:s248. 2024
Current and Future Treatment Options in the Management of Stage III NSCLC. 18:1478-1491. 2023
Integrating Smoking Cessation Into Low-Dose Computed Tomography Lung Cancer Screening: Results of the Ontario, Canada Pilot. 18:1323-1333. 2023
Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171). 18:813-819. 2023
Surgical, Radiation, and Systemic Treatments of Patients With Thymic Epithelial Tumors: A Systematic Review. 18:299-312. 2023
Breathing Life Into Lung Cancer Screening Trials. 17:1244-1246. 2022
Surgical, Radiation, and Systemic Treatments of Patients With Thymic Epithelial Tumors: A Clinical Practice Guideline. 17:1258-1275. 2022
EP04.02-002 International Consensus on Actions to Improve Lung Cancer Survival: Delphi Method in the International Cancer Benchmarking Partnership. 17:S260-S261. 2022
EP08.02-059 EGFR Tyrosine Kinase Inhibitors and Combination Strategies in First-line Treatment of Advanced NSCLC: A Network Meta-analysis. 17:S426-S427. 2022
MA08.03 Breathe Anew: Designing and Testing the Feasibility of a Novel Intervention for Lung Cancer Survivorship. 17:S71-S71. 2022
P1.15-10 Chronic Obstructive Pulmonary Disease Patients Receiving Immunotherapy for Lung Cancer: A Population-Based Study in Canada. 17:S124-S124. 2022
Ignoring the Obvious: Smoking Cessation Improves Survival. 17:596-598. 2022
OA04.01 Move For Surgery – A Novel Preconditioning Program to Optimize Health Before Thoracic Surgery: A Randomized Controlled Trial. 16:S852-S853. 2021
P55.02 Robotic Surgery in Canada: Are Patients Willing to Pay Out-of-Pocket?. 16:S1132-S1132. 2021
Tyrosine Kinase Inhibitor Therapy in Unresectable Locally Advanced NSCLC: Keep Holding Our Breaths or Time to Take a Breather?. 16:1607-1609. 2021
Critical Determinants of Cancer Treatment Outcomes: Smoking Must Be Addressed at the Highest Levels in Cancer Care. 16:891-893. 2021
MA07.04 Breathe Anew: Designing and Testing the Feasibility of a Novel Intervention for Lung Cancer Survivorship. 16:S157-S158. 2021
OA10.03 Reporting of Tobacco Use and Impact on Outcomes in Cancer Cooperative Group Clinical Trials: A Systematic Scoping Review. 16:S123-S124. 2021
P48.18 Chemo-Immunotherapy in First Line Extensive Stage Small Cell Lung Cancer (ES-SCLC): A Systematic Review and Meta-Analysis. 16:S506-S507. 2021
Canadian Multicenter Project on Standardization of Programmed Death-Ligand 1 Immunohistochemistry 22C3 Laboratory-Developed Tests for Pembrolizumab Therapy in NSCLC. 15:1328-1337. 2020
IA08 Mapping Mitochondrial Heterogeneity in Lung Cancer. 15:S4-S4. 2020
P1.10-05 Tobacco Retail Availability and Tobacco Cessation Among Lung Cancer Survivors. 14:S512-S512. 2019
A Phase I Study of Pomalidomide (CC-4047) in Combination with Cisplatin and Etoposide in Patients with Extensive-Stage Small-Cell Lung Cancer (vol 8, pg 423, 2013). 14:1484-1484. 2019
Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC. 13:1363-1372. 2018
Translation of Knowledge to Practice—Improving Awareness in NSCLC Molecular Testing. 13:1004-1011. 2018
OA 14.03 Ontario's Bundled Payment System for Systemic Therapy Supports Lung Cancer Trials. 12:S1782-S1783. 2017
P2.01-032 A Randomized Phase Ii Trial of Selumetinib + Platinum-pemetrexed (Pem-c) in Kras Wildtype (Wt)/Unknown NSCLC: CCTG Ind219. 12:S2081-S2081. 2017
Evaluating Cost-Effectiveness: An Essential Part of New Cancer Drug Approvals. 12:1461-1463. 2017
The Cost-Effectiveness of High-Risk Lung Cancer Screening and Drivers of Program Efficiency. 12:1210-1222. 2017
Response to Screening for Brain Metastases in Resectable Non–Small Cell Lung Cancer. 12:e22-e22. 2017
P1.05-067 Consultation with Medical Oncology Less Common in Elderly Patients with Resected Stage II Nonsmall Cell Lung Cancer. 12:S656-S657. 2017
A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207. 11:2018-2021. 2016
Comprehensive Clinical Staging for Resectable Lung Cancer: Clinicopathological Correlations and the Role of Brain MRI. 11:1970-1975. 2016
The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review. 11:989-1002. 2016
84P Metabolic stress to sensitize non-small cell lung cancer (NSCLC) to radiotherapy: Studies from bench to bedside. 11:S91-S91. 2016
Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. 11:312-323. 2016
Resource Utilization and Costs during the Initial Years of Lung Cancer Screening with Computed Tomography in Canada. 9:1449-1458. 2014
Canadian Anaplastic Lymphoma Kinase Study: A Model for Multicenter Standardization and Optimization of ALK Testing in Lung Cancer. 9:1255-1263. 2014
NCIC CTG IND.190 Phase I Trial of Dalotuzumab (MK-0646) in Combination with Cisplatin and Etoposide in Extensive-Stage Small-Cell Lung Cancer. 9:410-413. 2014
Clinical Utility of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Staging of Patients with Potentially Resectable Esophageal Cancer. 8:1563-1569. 2013
Challenges to Implementation of an Epidermal Growth Factor Receptor Testing Strategy for Non–Small-Cell Lung Cancer in a Publicly Funded Health Care System. 8:1136-1141. 2013
Improving the Quality of Lung Cancer Care in Ontario: The Lung Cancer Disease Pathway Initiative. 8:876-882. 2013
Phase 2 Study of Pemetrexed and Itraconazole as Second-Line Therapy for Metastatic Nonsquamous Non–Small-Cell Lung Cancer. 8:619-623. 2013
A Phase I Study of Pomalidomide (CC-4047) in Combination with Cisplatin and Etoposide in Patients with Extensive-Stage Small-Cell Lung Cancer. 8:423-428. 2013
KRAS Mutation Spectrum Notably Diverges between Non-small Cell Lung and Colorectal Carcinomas: In Response. 7:774-774. 2012
Brief Report: A Phase II Study of Sunitinib in Malignant Pleural Mesothelioma. The NCIC Clinical Trials Group. 6:1950-1954. 2011
Computed Tomography Screening for Lung Cancer without a Smoking Cessation Program—Not a Cost-Effective Idea. 6:1781-1783. 2011
A Systematic Review and Canadian Consensus Recommendations on the Use of Biomarkers in the Treatment of Non-small Cell Lung Cancer. 6:1379-1391. 2011
Positron Emission Tomography-Computed Tomography Compared with Invasive Mediastinal Staging in Non-small Cell Lung Cancer: Results of Mediastinal Staging in the Early Lung Positron Emission Tomography Trial. 6:1367-1372. 2011
Selecting Patients with Extensive-Stage Small Cell Lung Cancer for Prophylactic Cranial Irradiation by Predicting Brain Metastases. 6:808-812. 2011
Aromatase Inhibitor Exemestane has Antiproliferative Effects on Human Mesothelioma Cells. 6:583-591. 2011
Lovastatin Sensitizes Lung Cancer Cells to Ionizing Radiation: Modulation of Molecular Pathways of Radioresistance and Tumor Suppression. 6:439-450. 2011
Positron Emission Tomography with 18Fluorodeoxyglucose in Radiation Treatment Planning for Non-small Cell Lung Cancer: A Systematic Review. 6:86-97. 2011
First-Line Systemic Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer: A Systematic Review. 5:260-274. 2010
A Phase I/II Study of GTI-2040 Plus Docetaxel as Second-Line Treatment in Advanced Non-small Cell Lung Cancer: A Study of the PMH Phase II Consortium. 4:1163-1169. 2009
The Management of Thymoma: A Systematic Review and Practice Guideline. 4:911-919. 2009
Anticoagulation and Bleeding: A Pooled Analysis of Lung Cancer Trials of the NCIC Clinical Trials Group. 4:586-594. 2009
Association of Phosphorylated Epidermal Growth Factor Receptor with Survival in Patients with Locally Advanced Non-small Cell Lung Cancer Treated with Radiotherapy. 3:716-722. 2008
Zoledronic Acid and Survival in Patients with Metastatic Bone Disease from Lung Cancer and Elevated Markers of Osteoclast Activity. 3:228-236. 2008
M20-01: The cost of care for patients with lung cancer. 2:S209-S210. 2007
P1-096: 18Fluorodeoxyglucose Positron Emission Tomography in the diagnosis and staging of lung cancer: a systematic review and practitioner guideline in Ontario, Canada. 2:S588-S588. 2007
P1-097: 18Fluorodeoxyglucose Positron Emission Tomography and co-registered computed tomography for radiation treatment planning in lung cancer: a systematic review. 2:S588-S589. 2007
P1-117: The development of a practice guideline for the management of malignant thymoma through a formal consensus process.. 2:S597-S597. 2007
P1-185: Progress report: Eastern Cooperative Oncology Group (ECOG) E5597, an intergroup phase iii randomized double blind chemoprevention trial of selenium supplementation in resected stage i non small cell lung cancer. 2:S811-S811. 2007
P1-248: Lung cancer guideline development in ontario: impact on policy and practice. 2:S837-S837. 2007
P2-165: A phase I/II study of concurrent pemetrexed/cisplatin/radiation in stage IIIa/b non-small cell lung cancer. 2:S635-S635. 2007
P3-091: A Phase I study of continuous oral treatment with the triple angiokinase inhibitor BIBF 1120 together with pemetrexed in previously treated patients with non-small cell lung cancer. 2:S717-S718. 2007
Chemotherapy for Relapsed Small Cell Lung Cancer: A Systematic Review and Practice Guideline. 2:348-354. 2007
A Phase I Evaluation of Oral CI-1033 in Combination with Paclitaxel and Carboplatin as First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer. 1:1010-1019. 2006
A Phase I Evaluation of Oral CI-1033 in Combination with Paclitaxel and Carboplatin as First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer. 1:1010-1019. 2006
Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline. 1:1042-1058. 2006
Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline. 1:1042-1058. 2006
The Use of Chemotherapy in Patients with Advanced Malignant Pleural Mesothelioma: A Systematic Review and Practice Guideline. 1:591-601. 2006
Management of unresected stage III non-small cell lung cancer: a systematic review.. 1:377-393. 2006
Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review.. 1:367-376. 2006
Practitioner feedback on lung cancer practice guidelines in Ontario.. 1:10-18. 2006

Journal of Thoracic Oncology Journal

Overview

publication venue for

has subject area

Identity

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)